Microvessel Density (MVD) in Locally Advanced Breast Cancer

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2019 May 26

PMID 31128060

Citations 5

Authors

Syama Krishnapriya

Basawantrao Malipatil

Suresh Surekha

Shirley Sundersingh

Velusamy Sridevi

Balasubramanian Ananthi

Ganesarajah Selvaluxmy

Trivadi S Ganesan

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to evaluate microvessel density (MVD) by expression of CD31 and CLEC14A in core biopsies from previously untreated patients with locally advanced breast cancer (LABC) and assess its prognostic significance. Methods: MVD was evaluated in core needle biopsies (n = 92), collected prior to any treatment, from patients who were diagnosed with locally advanced breast cancer (LABC). Immunohistochemistry for expression of CD31 and CLEC14A were performed on these tumours. The median duration of follow-up was 9.3 years. The effect of prognostic factors on disease free survival (DFS) and overall survival (OS) was assessed using a Log rank test and Cox regression model. Results: The clinical factors such as age, clinical nodal stage, stage and pathological nodal status were found to be significant in predicting overall survival by multivariate analysis (P<0.05). Out of 92, 52 tumours had blood vessels expressing CD31, whereas in the remainder, there was no expression. The mean and median MVD of CD31 in 92 tumours was 38 and 5.5 respectively, and it was not a significant factor for predicting disease free survival or overall survival. When we considered the tumours (n=52) which expressed CD31, patients who had very high MVD (>100), had inferior progression free survival and overall survival (P=0.5). There was no expression of CLEC14A in any of the core needle biopsies whereas it was expressed in specimens from mastectomy from the same patient. Conclusion: This is the first report of MVD in LABC prior to any treatment. The results suggest angiogenesis could be a prognostic factor in LABC.

Citing Articles

The potential of lenvatinib in breast cancer therapy.

Shang Y, Liu T, Wang W Med Oncol. 2024; 41(9):233.

PMID: 39172293 DOI: 10.1007/s12032-024-02477-4.

Diagnostic value of one-stop CT energy spectrum and perfusion for angiogenesis in colon and rectum cancer.

Zhao L, Zhou W, Fu Y, Ge Y, Feng L, Wang X BMC Med Imaging. 2024; 24(1):116.

PMID: 38773384 PMC: 11106941. DOI: 10.1186/s12880-024-01291-8.

Vascularity and Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging.

Frankhouser D, Dietze E, Mahabal A, Seewaldt V Front Radiol. 2023; 1:735567.

PMID: 37492179 PMC: 10364989. DOI: 10.3389/fradi.2021.735567.

LncRNA LINC01857 reduces metastasis and angiogenesis in breast cancer cells via regulating miR-2052/CENPQ axis.

Qian W, Yang L, Ni Y, Yin F, Qin L, Yang Y Open Med (Wars). 2022; 17(1):1357-1367.

PMID: 36046633 PMC: 9372711. DOI: 10.1515/med-2022-0525.

Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.

Minemura H, Takagi K, Sato A, Yamaguchi M, Hayashi C, Miki Y Breast Cancer. 2021; 28(4):915-926.

PMID: 33713004 DOI: 10.1007/s12282-021-01228-x.

References

Shetty P . India faces growing breast cancer epidemic. Lancet. 2012; 379(9820):992-3. DOI: 10.1016/s0140-6736(12)60415-2. View

Dachs G, Chaplin D . Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol. 1998; 8(3):208-16. DOI: 10.1016/s1053-4296(98)80046-5. View

Mura M, Swain R, Zhuang X, Vorschmitt H, Reynolds G, Durant S . Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene. 2011; 31(3):293-305. DOI: 10.1038/onc.2011.233. View

Rau K, Huang C, Chiu T, Chen Y, Lu C, Liu C . Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Exp Ther Med. 2012; 4(2):231-236. PMC: 3460296. DOI: 10.3892/etm.2012.594. View

Weidner N . Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol. 2000; 31(4):403-5. DOI: 10.1053/hp.2000.6724. View

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

Charpin C, Dales J, Garcia S, Carpentier S, Djemli A, Andrac L . Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res. 2004; 10(17):5815-9. DOI: 10.1158/1078-0432.CCR-04-0021. View

Toi M, Kashitani J, Tominaga T . Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer. 1993; 55(3):371-4. DOI: 10.1002/ijc.2910550305. View

Horak E, Leek R, Klenk N, Lejeune S, Smith K, Stuart N . Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992; 340(8828):1120-4. DOI: 10.1016/0140-6736(92)93150-l. View

10.

Shanta V, Swaminathan R, Rama R, Radhika R . Retrospective analysis of locally advanced noninflammatory breast cancer from Chennai, South India, 1990-1999. Int J Radiat Oncol Biol Phys. 2007; 70(1):51-8. DOI: 10.1016/j.ijrobp.2007.05.050. View

11.

Mohammed R, Ellis I, Mahmmod A, Hawkes E, Green A, Rakha E . Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol. 2011; 24(6):774-85. DOI: 10.1038/modpathol.2011.4. View

12.

Seddon A, Cuellar S, Haaf C . The life, death, and attempted rebirth of bevacizumab in breast cancer. J Oncol Pharm Pract. 2013; 20(6):433-44. DOI: 10.1177/1078155213510193. View

13.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

14.

Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga J . Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(12):1351-60. DOI: 10.1016/S1470-2045(14)70444-9. View

15.

Felix A, Lenz P, Pfeiffer R, Hewitt S, Morris J, Patel D . Relationships between mammographic density, tissue microvessel density, and breast biopsy diagnosis. Breast Cancer Res. 2016; 18(1):88. PMC: 4995674. DOI: 10.1186/s13058-016-0746-9. View

16.

Honkoop A, van Diest P, de Jong J, Linn S, Giaccone G, Hoekman K . Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1998; 77(4):621-6. PMC: 2149927. DOI: 10.1038/bjc.1998.99. View

17.

Heath V, Bicknell R . Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 2009; 6(7):395-404. DOI: 10.1038/nrclinonc.2009.52. View

18.

MAYERS M, Seshadri R, Raymond W, McCaul K, Horsfall D . Tumor microvascularity has no independent prognostic significance for breast cancer. Pathology. 1998; 30(2):105-10. DOI: 10.1080/00313029800169046. View

19.

Siemann D . The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev. 2010; 37(1):63-74. PMC: 2958232. DOI: 10.1016/j.ctrv.2010.05.001. View

20.

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View